Blueprint Medicines Corporation (BPMC)
Upgrades & Downgrades
Latest BPMC news
Blueprint Medicines: A Slow But Steady Blueprint For Success
14 December 2022
Blueprint Medicines Corporation has multiple approved drugs and potential label expansions. Sales have not been as good as expected.
Blueprint Medicines (BPMC) Files Ayvakit sNDA for Indolent SM
23 November 2022
Blueprint Medicines (BPMC) submits a supplemental new drug application for its lead drug, Ayvakit, for the treatment of indolent systemic mastocytosis to the FDA.
Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark
2 November 2022
Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.
Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?
5 October 2022
Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to generate incremental sales and combat stiff competition.
Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal
15 September 2022
Blueprint has a few recently approved therapies, and has recently sold royalties for over $1 billion. While this limits revenue potential now, the profits can be leveraged back into advancing the pipe...
Blueprint Medicines (BPMC) Rises 68.2% in 3 Months: Here's Why
12 September 2022
Blueprint Medicines' (BPMC) Ayvakit, approved for treating PDGFRA Exon 18 mutant gastrointestinal stromal tumors, is witnessing strong uptake. The drug's label expansion studies also hold promise.
Blueprint Medicines' (BPMC) Ayvakit Meets Goal in PIONEER Study
18 August 2022
Blueprint Medicines (BPMC) posts top-line data from part 2 of the PIONEER study evaluating Ayvakit in patients with non-advanced systemic mastocytosis. Shares down.
Blueprint Medicines Stock Hammered As 'Long-Awaited' Test Results Disappoint
17 August 2022
Blueprint unveiled the "long-awaited" results of its study in indolent systemic mastocytosis on Wednesday, and the biotech stock crashed. The post Blueprint Medicines Stock Hammered As 'Long-Awaited' ...
Blueprint's stock falls 11% after sharing new Phase 2 data for its rare-disease therapy
17 August 2022
Shares of Blueprint Medicines Corp. BPMC, -2.00% tumbled 11.7% in premarket trading on Tuesday after the company said a Phase 2 clinical trial evaluating Ayvakit in patients with non-advanced systemic...